Ann: Phosphagenics Arbitration Award Issued, page-144

This company did it the right way by getting EU approval first and then seeking investors outside the market.  A fraction of share outstanding compared to POH. Now seeking FDA approval. Just heard the CEO talking about it. He said companies overstate the importance of efficacy to regulator (EU & FDA). The regulators are more concerned with long term safety. I know, If only and what ifs ....Pointless now other than to educate for future investments.

Clinuvel Pharmaceuticals Limited (CUV) is a biopharmaceutical company focused on developing drugs for the treatment of a range of severe skin disorders. CUV's lead compound is SCENESSE (afamelanotide), a drug targeting erythropoietic protoporphyria (EPP).